On November 6, Xiansheng Pharmaceutical Group announced that the new drug marketing application for the highly selective second-generation JAK1 inhibitor zeprixitinib for the treatment of moderate to severe active rheumatoid arthritis in cooperation with Lingke Pharmaceutical Co., Ltd. has been officially accepted by the Drug Evaluation Center of the China National Drug Administration. This is the second indication for zepcitinib to enter the registration review stage in China.

Zhitongcaijing · 2d ago
On November 6, Xiansheng Pharmaceutical Group announced that the new drug marketing application for the highly selective second-generation JAK1 inhibitor zeprixitinib for the treatment of moderate to severe active rheumatoid arthritis in cooperation with Lingke Pharmaceutical Co., Ltd. has been officially accepted by the Drug Evaluation Center of the China National Drug Administration. This is the second indication for zepcitinib to enter the registration review stage in China.